Virtu Financial LLC Metacrine, Inc. Transaction History

Virtu Financial LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$0.36 - $0.63 $10,248 - $17,934	28,468 New	28,468 $14,000
Q1 2022 May 17, 2022	SELL	$0.43 - $0.7 $52,617 - $85,656	-122,366 Closed	0 $0
Q4 2021 Feb 17, 2022	BUY	$0.64 - $3.83 $78,314 - $468,661	122,366 New	122,366 $82,000
Q3 2021 Nov 12, 2021	SELL	$2.61 - $3.84 $51,341 - $75,536	-19,671 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$3.37 - $5.73 $66,291 - $112,714	19,671 New	19,671 $75,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.